Lutetium Lu177 Edotreotide

Summary

Lutetium‑177 edotreotide (177Lu‑DOTATOC) is a radiolabeled somatostatin analogue used in peptide‑receptor radionuclide therapy (PRRT). The molecule binds somatostatin receptors, especially SSTR2, on neuroendocrine and other SSTR‑expressing tumours and delivers beta‑particle radiation to destroy cancer cells. It is administered intravenously under prescription and is approved for clinical use in SSTR‑positive neuroendocrine neoplasms, with exploratory applications in breast neuroendocrine carcinoma, adrenocortical carcinoma, and meningioma.

Mechanism of Action

The DOTA‑conjugated octreotide analogue (edotreotide) has high affinity for somatostatin receptor subtype 2. After intravenous infusion it binds to SSTR2 on tumour cell membranes, is internalised, and the chelated Lu‑177 emits β‑particles (max energy ~0.5 MeV) that cause localized DNA damage and cell death. The same radionuclide also emits low‑energy γ‑photons, enabling post‑therapy scintigraphic imaging and dosimetry.

What the Research Shows

Case‑report data show a 69‑year‑old woman with neuroendocrine breast carcinoma achieving partial remission after 177Lu‑DOTATOC PRRT. A prospective series of 27 patients relapsed after prior 90Y‑DOTATOC reported partial remission in two, minor response in five, stable disease in twelve and progression in eight, with no serious adverse events. In meningioma, a phase‑II trial of combined 90Y‑ and 177Lu‑DOTATOC reported stable disease in 23 of 34 patients and a median survival of 8.6 years; severe hematologic toxicity occurred in three patients. A small ACC cohort (2 treated) achieved disease control lasting 4–12 months. A systematic review of meningioma dosimetry indicated tumour absorbed doses of 0.1–1.5 Gy/GBq, lower than in neuroendocrine tumours.

Reported Benefits

Evidence suggests 177Lu‑DOTATOC can induce tumour shrinkage or disease stabilisation in SSTR‑positive neuroendocrine tumours, with partial remission reported in some patients and a favourable safety profile compared with 90Y‑based therapy. In meningioma, stable disease and prolonged survival have been observed, especially when tumour uptake is high. The beta emission provides therapeutic effect while the accompanying gamma emission permits imaging for response assessment.

Limitations of the Evidence

Most data derive from small case series, single‑centre studies, or retrospective analyses; no large randomised trials have been published. The number of patients treated for non‑neuroendocrine indications (breast carcinoma, ACC, meningioma) is very limited, making efficacy conclusions tentative. Dosimetry methods vary widely, and optimal activity per cycle remains undefined. Long‑term outcomes beyond a few years are insufficiently characterised.

Safety Considerations

Across studies, 177Lu‑DOTATOC was generally well tolerated. Reported toxicities were mostly grade 1–2 hematologic changes (e.g., modest haemoglobin decline) and mild renal function shifts; severe haematotoxicity occurred in a minority of meningioma patients (3/34) and one case of severe renal toxicity was noted. No serious adverse events were recorded in the neuroendocrine tumour cohort. Prior 90Y therapy can increase creatinine, but 177Lu treatment did not significantly worsen renal parameters in the reported series.

How It Is Administered

The agent is administered intravenously as a sterile solution, typically as a single infusion per treatment cycle. Activity is expressed in megabecquerels (e.g., around 7,400 MBq in reported protocols). Multiple cycles may be given at intervals of several weeks to months, with post‑therapy imaging used to assess distribution and calculate absorbed dose.

Routes of Administration

Goals & Uses

• treatment of metastatic gastroenteropancreatic neuroendocrine tumoursOncologyHigh
• Palliation of symptoms in functional NETsSymptom ManagementModerate
• Tumor response and disease control in midgut NETsOncologyHigh
• Treatment of other SSTR2-expressing tumors (paraganglioma, pheochromocytoma, meningioma)Oncology / InvestigationalLow
• Treatment of somatostatin receptor-positive GEP-NETsOncology / Neuroendocrine Tumor ManagementHigh
• palliation of hormone‑related symptomsSymptom ControlModerate

Contraindications

• Prior maximum cumulative radiation dose to kidneysRadiation DosimetryHigh
• Severe renal impairment (eGFR <30 mL/min)RenalModerate
• Severe renal impairment (GFR <30 mL/min)Renal FunctionHigh
• PregnancyPopulationHighPotential fetal risk or insufficient safety data
• BreastfeedingPopulationHighPotential transfer into breast milk or insufficient safety data
• Severe bone marrow suppressionHematologicHigh

Adverse Effects

• renal toxicityRenalUncommon
• Myelosuppression (thrombocytopenia, leukopenia, anemia)HematologicCommon
• Nausea/vomitingGastrointestinalCommon
• Nausea and vomitingGastrointestinalCommon
• FatigueGeneralCommonLow energy or tiredness
• Radiation-induced hepatotoxicityHepaticRare
• haematologic toxicity (thrombocytopenia, neutropenia)HematologicCommon
• Secondary myelodysplastic syndrome / leukemiaHematologicRare
• NephrotoxicityRenalUncommon

Drug Interactions

• concomitant nephrotoxic agents (e.g., aminoglycosides, NSAIDs)Moderate
• Myelosuppressive chemotherapyHigh
• Long-acting somatostatin analogues (octreotide LAR, lanreotide)Moderate
• Nephrotoxic drugs (aminoglycosides, NSAIDs, cisplatin)High

Population Constraints

• Pediatric patientsAgeRelative
• Children (<18 y)AgeRelative
• Elderly patients (>75 years)AgeRelative
• Elderly (>75 y)AgeRelative
• Patients with renal impairmentOrgan ImpairmentRelative
• Patients with extensive bone marrow involvement by tumorDisease CharacteristicsRelative

Regulatory Status

• European UnionInvestigationalclinical trial phase III (EurA) as of 2024
• United StatesInvestigationalunder IND for PRRT of SSTR2‑positive NETs
• United KingdomUnknownUsed in specialized centers; regulatory approval status in UK post-Brexit requires verification with MHRA.

The FDA approved lutetium Lu-177 edotreotide (OCREOTIDE-based DOTA conjugate; brand: PluvictoTM is a different compound; edotreotide as therapeutic known as ITM-11) in 2024 for GEP-NETs. Distinct from lutetium Lu-177 dotatate (Lutathera). 177Lu-edotreotide (DOTATOC) is approved in some jurisdictions; regulatory status varies by exact formulation and jurisdiction.

Evidence & Sources

• 177Lu-DOTATOC Peptide Receptor Radionuclide Therapy in a Patient With Neuroendocrine Breast Carcinoma and Breast Invasive Ductal Carcinoma
  Journal ArticleLowLiu Q, et al.2020-01-01T00:00:00.000000Z
• Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC
  Journal ArticleModerateForrer F, et al.2005-01-01T00:00:00.000000Z
• Semi-automatic 3D-volumetry of liver metastases from neuroendocrine tumors to improve combination therapy with 177Lu-DOTATOC and 90Y-DOTATOC
  Journal ArticleLowCieciera M, et al.2016-01-01T00:00:00.000000Z
• Treatment With 90Y/177Lu-DOTATOC in Patients With Metastatic Adrenocortical Carcinoma Expressing Somatostatin Receptors
  Journal ArticleLowGrisanti S, et al.2020-01-01T00:00:00.000000Z
• Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical trial
  Journal ArticleModerateMarincek N, et al.2015-01-01T00:00:00.000000Z
• 177Lu-labeled somatostatin receptor targeted radionuclide therapy dosimetry in meningioma: a systematic review
  Journal ArticleHighBoursier C, et al.2024-01-01T00:00:00.000000Z

Frequently Asked Questions